Stribild (HIV)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 23
6.1 Efficacy 24
6.2 Safety 25
6.3 SWOT Analysis 25
6.4 Forecast 28
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 31
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 HIV Prevalence 33
7.4.2 Percent Drug-Treated Patients 33
7.4.3 General Pricing Assumptions 34
7.4.4 Individual Drug Assumptions 35
7.4.5 Generic Erosion 35
7.5 Physicians and Specialists Included in this Study 36
7.5.1 Survery of Prescribing Physicians 37
7.6 About the Authors 37
7.6.1 Authors 37
7.6.2 Global Head of Healthcare 38
7.7 About GlobalData 39
7.8 Contact Us 39
7.9 Disclaimer 39